COMP <GO>
TGTX vs JNJ // ALTMAN Z-SCORE & DEBT/EQUITY
TG Therapeutics Inc. (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: TGTX 7
— JNJ 7
▲ ALTMAN Z-SCORE & DEBT/EQUITY LEADER: TGTX
LAST: $61.18 (+5.34%) • MKT CAP: $8.89B
balance-sheet
12.92
LAST: $273.20 (-0.73%) • MKT CAP: $662.49B
balance-sheet
5.59
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (TGTX VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | TGTX | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 83.70% | 67.90% | +15.80 | TGTX | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 12.00% | 25.50% | -13.50 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation | 73.3x | 18.5x | +54.80 | JNJ | /valuation <GO> |
| Free Cash Flow Yield | -0.28% | 2.97% | -3.25 | JNJ | /fcf-yield <GO> |
| Operating Margin | 20.00% | 34.70% | -14.70 | JNJ | /operating-margins <GO> |
| Net Profit Margin | 68.00% | 28.50% | +39.50 | TGTX | /net-margins <GO> |
| Revenue Growth (YoY) | 87.30% | 6.00% | +81.30 | TGTX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity ACTIVE | 12.92 | 5.59 | +7.33 | TGTX | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 8/9 | -2.00 | JNJ | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.50% | 7.20% | -0.70 | TGTX | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 69.7 | 60.4 | +9.36 | TGTX | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.87 | 1.08 | -0.21 | JNJ | /macro-sensitivity <GO> |
| Forward P/E Multiple | 16.7x | 23.0x | -6.30 | TGTX | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $8.89B | $662.49B | -$653.60B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | TGTX REV | JNJ REV | TGTX GROSS % | JNJ GROSS % | TGTX FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $616.3M | $94.19B | 83.7% | 67.9% | -$25.0M | $19.70B |
| FY 2024 | $329.0M | $88.82B | 88.3% | 69.1% | -$40.6M | $19.84B |
| FY 2023 | $233.7M | $85.16B | 44.0% | 44.0% | -$41.9M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
TGTX // BETA 0.87
JNJ // BETA 1.08